XOMA Royalty Stock Quote XOMA - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

29.24

Bid

24.00

Ask

30.66

Volume

35,990

27.61 Day's Range 29.49

13.48 52 Week Range 30.36

Market Cap

340.311M

Previous Close

28.92

Open

29.00

Last Trade

539

29.24

(priorref)

Last Trade Time

Financial Volume

$ 1,045,857

VWAP

29.0597

Average Volume (3m)

17,941

Shares Outstanding

11,638,553

Dividend Yield

PE Ratio

-8.34

Earnings Per Share (EPS)

-3.51

Revenue

4.76M

Net Profit

-40.83M

XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.xoma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

XOMA Royalty Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XOMA. The last closing price for XOMA Royalty was $28.92. Over the last year, XOMA Royalty shares have traded in a share price range of $ 13.48 to $ 30.36.

XOMA Royalty currently has 11,638,553 shares outstanding. The market capitalization of XOMA Royalty is $336.59 million. XOMA Royalty has a price to earnings ratio (PE ratio) of -8.34.

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends...

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from...

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the...

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired...

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and...

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or...

Actym Therapeutics Appoints Thomas Smart as CEO

Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif., April 24, 2024 BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to...

XOMA Corporation Announces Closing of Tender Offer

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech...

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash...

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (“XOMA” or the “Company”; Nasdaq: XOMA) entered into a merger agreement to...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.66	6.0188542422	27.58	30.36	27.07	34424	28.75772487	CS
4	5.83	24.9038872277	23.41	30.36	22.88	25861	27.39154718	CS
12	3.66	14.3080531665	25.58	30.36	21.27	17941	25.88008385	CS
26	8.33	39.837398374	20.91	30.36	19.5	18052	24.87259419	CS
52	13.78	89.1332470893	15.46	30.36	13.48	21787	20.23497885	CS
156	-4.04	-12.1394230769	33.28	37.5	13.48	29342	20.75752531	CS
260	10.07	52.5299947835	19.17	46.32	13.48	36755	23.8962108	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.55M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.51M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	258.51k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.05M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.68M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.89M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	714.54k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.01M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	404.94M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.51M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.16M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.42M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.64M